Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lipid nanoparticle drug delivery tech
Biotech
Verve halts VERVE-101 enrollment, focuses on 2nd PCSK9 editor
The patient who had two grade 3 side effects after receiving VERVE-101 was asymptotic, and lab abnormalities resolved within days.
Max Bayer
Apr 2, 2024 7:00am
Gritstone taps Genevant to power up infectious disease vaccines
Aug 15, 2023 10:00am
Bayer bags access to delivery tech behind Pfizer's Comirnaty
Jun 7, 2023 8:30am
Moderna’s protein replacement therapy passes early clinical test
May 19, 2023 10:10am
Moderna pays Generation Bio $76M in lipid nanoparticle collab
Mar 23, 2023 10:58am
Potential preeclampsia treatment delivers mRNA to the placenta
Feb 21, 2023 9:45am